Compare HTGC & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HTGC | ARQT |
|---|---|---|
| Founded | 2003 | 2016 |
| Country | United States | United States |
| Employees | 50 | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.6B |
| IPO Year | N/A | 2020 |
| Metric | HTGC | ARQT |
|---|---|---|
| Price | $15.59 | $21.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | $18.86 | ★ $34.00 |
| AVG Volume (30 Days) | 1.8M | ★ 2.0M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 12.13% | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $376,072,000.00 |
| Revenue This Year | $11.18 | $34.85 |
| Revenue Next Year | $5.24 | $29.39 |
| P/E Ratio | $8.61 | ★ N/A |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $13.70 | $12.72 |
| 52 Week High | $19.67 | $31.77 |
| Indicator | HTGC | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 49.70 | 47.22 |
| Support Level | $15.22 | $21.12 |
| Resistance Level | $15.96 | $21.84 |
| Average True Range (ATR) | 0.31 | 0.99 |
| MACD | -0.05 | 0.13 |
| Stochastic Oscillator | 40.12 | 67.04 |
Hercules Capital Inc is a specialty finance company focused on providing senior secured loans to high-growth, venture capital-backed, and institutional-backed companies in a variety of technology and life sciences industries. The company's primary business objectives are to increase its net income, net investment income, and net asset value (NAV) through its investments mainly in structured debt or senior secured debt instruments of venture capital-backed and institutional-backed companies across a variety of technology-related industries at attractive yields. It finances companies belonging to computer software and hardware, networking systems, semiconductors, medical devices, bio-pharmaceutical, and other related sectors.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.